We bring you the latest news from the healthcare about the health care in the United Kingdom.

zaterdag 22 september 2018

The Lancet: [Correspondence] Partnerships with the alcohol industry: opportunities and risks

[Correspondence] Partnerships with the alcohol industry: opportunities and risks
The continuing health harms of alcohol1 require action not inaction.2 A range of effective policy interventions are available, and Public Health England (PHE) has been prominent in bringing all of these to the attention of policy makers.3 In The Lancet, Mark Petticrew and colleagues4 discuss PHE's partnership with the charity Drinkaware and suggest that such collaborations could be at the expense of public health.
Read more

[Department of Error] Department of Error
Kruk ME, Gage AD, Joseph NT, Danaei G, García-Saisó S, Salomon JA. Mortality due to low-quality health systems in the universal health coverage era: a systematic analysis of amenable deaths in 137 countries Lancet 2018; https://doi.org/10.1016/S0140-6736(18)31668-4—In figure 2 of this Article (published Online First on Sept 5, 2018), the y axis should read "deaths in 100 000s". The affiliation for Prof Salomon should read "Center for Health Policy and Center for Primary Care and Outcomes Research, Stanford University School of Medicine, Stanford, CA, USA".
Read more

[Comment] 10 years after the Commission on Social Determinants of Health: social injustice is still killing on a grand scale
In 2008, WHO launched the final report of the Commission on Social Determinants of Health (CSDH) that concluded "social injustice is killing people on a grand scale".1 A decade later, how should we judge the CSDH's impact? A Google search for the CSDH yields 156 000 results and the accompanying Lancet paper has had 932 citations.2 The CSDH led to two World Health Assembly resolutions and more than 100 countries adopted the Rio Political Declaration on Social Determinants of Health in 2011.3 The CSDH's report has become a foundational text for how crucial social determinants are to health and health equity.
Read more

[Articles] Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
The addition of ustekinumab to standard-of-care treatment resulted in better efficacy in clinical and laboratory parameters than placebo in the treatment of active systemic lupus erythematosus and had a safety profile consistent with ustekinumab therapy in other diseases. The results of this study support further development of ustekinumab as a novel treatment in systemic lupus erythematosus.
Read more

[Comment] Ustekinumab: a promising new drug for SLE?
In The Lancet, Ronald van Vollenhoven and colleagues1 report a positive multicentre double-blind phase 2 randomised, placebo-controlled trial with ustekinumab, an anti-interleukin-12/23 (IL-12/23) monoclonal antibody, in 102 patients aged 18–75 years with active systemic lupus erythematosus (93 women and nine men). The design of the study is common for trials of biotherapies in patients with systemic lupus erythematosus: ustekinumab was assessed as add-on treatment to standard-of-care therapy in patients with active disease, excluding severe cases with active glomerulonephritis, systemic vasculitis, or CNS involvement.
Read more